Article

Savolitinib: A Promising Targeting Agent for Cancer

2023-08-07

Abstract excerpt

Savolitinib is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase, primarily developed for the treatment of non-small cell lung cancer (NSCLC) with MET mutations. It is also being investigated as a treatment for breast, head and neck, colorectal, gastric, pancreatic, and other gastrointestinal cancers. In both preclinical and clinical studies, it has d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e7d0f0a4-a66a-5c6c-b04f-bc6d0ec8618b
DOI: 10.20944/preprints202308.0190.v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Savolitinib: A Promising Targeting Agent for CancerDOI 10.20944/preprints202308.0190.v2Read

Savolitinib for non-small cell lung cancer.Semantic proximity Read

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read

Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.Semantic proximity Read

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).Semantic proximity Read

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.Semantic proximity Read

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read

Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer.Semantic proximity Read

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.Semantic proximity Read

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read